We obtained expression data for 32 cancer types and DFI data for the corresponding samples and observed that higher expression of NR2F6 in CESC, KIRP, PRAD and ACC was associated with worse DFI, and higher expression of NR2F6 in the PCPG was associated with better DFI (Fig 2A). This evidence concerns the gene NR2F6 and prostate adenocarcinoma.